Abstract:Mutations in the COL1A1 and COL1A2 genes, which encode type I collagen, are present in around 85%–90% of osteogenesis imperfecta (OI) patients. Because type I collagen is the principal protein composition of bones, any changes in its gene sequences or synthesis can severely affect bone structure. As a result, skeletal deformity and bone frailty are defining characteristics of OI. Homozygous oim/oim mice are utilized as models of severe progressive type III OI. Bone adapts to external forces by altering its mass and architecture. Previous attempts to leverage the relationship between muscle and bone involved using a soluble activin receptor type IIB‐mFc (sActRIIB‐mFc) fusion protein to lower circulating concentrations of activin A and myostatin. These two proteins are part of the TGF‐β superfamily that regulate muscle and bone function. While this approach resulted in increased muscle masses and enhanced bone properties, adverse effects emerged due to ligand promiscuity, limiting clinical efficacy and obscuring the precise contributions of myostatin and activin A. In this study, we investigated the musculoskeletal and whole‐body metabolism effect of treating 5‐week‐old wildtype (Wt) and oim/oim mice for 11 weeks with either control antibody (Ctrl‐Ab) or monoclonal anti‐activin A antibody (ActA‐Ab), anti‐myostatin antibody (Mstn‐Ab), or a combination of ActA‐Ab and Mstn‐Ab (Combo). We demonstrated that ActA‐Ab treatment minimally impacts muscle mass in oim/oim mice, whereas Mstn‐Ab and Combo treatments substantially increased muscle mass and overall lean mass regardless of genotype and sex. Further, while no improvements in cortical bone microarchitecture were observed with all treatments, minimal improvements in trabecular bone microarchitecture were observed with the Combo treatment in oim/oim mice. Our findings suggest that individual or combinatorial inhibition of myostatin and activin A alone is insufficient to robustly improve femoral biomechanical and microarchitectural properties in severely affected OI mice. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

Activin A promotes the development of acquired heterotopic ossification and is an effective target for disease attenuation in mice

Activin A marks a novel progenitor cell population during fracture healing and reveals a therapeutic strategy

Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro.

Activin receptor type 2A (ACVR2A) functions directly in osteoblasts as a negative regulator of bone mass

Combinatorial Inhibition of Myostatin and Activin A Improves Femoral Bone Properties in the G610C Mouse Model of Osteogenesis Imperfecta

Administration of soluble activin receptor 2B increases bone and muscle mass in a mouse model of osteogenesis imperfecta

Novel ActRIIB ligand trap increases muscle mass and improves bone geometry in a mouse model of severe osteogenesis imperfecta

Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery

How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva

Whole‐Body Metabolism and the Musculoskeletal Impacts of Targeting Activin A and Myostatin in Severe Osteogenesis Imperfecta

AAV-Mediated Targeting of the Activin A-ACVR1R206H Signaling in Fibrodysplasia Ossificans Progressiva

Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling

Activin receptor antagonists for cancer-related anemia and bone disease

Immunohistochemical Detection of Activin A, Follistatin, and Activin Receptors During Fracture Healing in the Rat

Targeted overexpression of osteoactivin in cells of osteoclastic lineage promotes osteoclastic resorption and bone loss in mice

The Effect of MMP-2 Inhibitor 1 on Osteogenesis and Angiogenesis During Bone Regeneration.

Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage

Activin A more prominently regulates muscle mass in primates than does GDF8

Local administration of activin promotes fracture healing in the rat fibula fracture model

Single cell analysis reveals inhibition of angiogenesis attenuates the progression of heterotopic ossification in Mkx−/− mice

Activin signaling disruption in the cochlea does not influence hearing in adult mice